ArticleInternational journal of clinical oncology2022

Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.

Shintaro Narita et al.PubMed ↗Publisher ↗

No numbers read from the abstract.